Related Experiment Video
Updated: Jul 13, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Sirolimus monotherapy in liver transplantation
F Di Benedetto1, S Di Sandro, N De Ruvo
1Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, Italy. f.diben@virgilio.it
Transplantation Proceedings
|August 19, 2007
Summary
Sirolimus (SRL) monotherapy effectively treated complications from calcineurin inhibitors, including nephrotoxicity and neurotoxicity, in liver transplant patients. It also showed promise in managing Kaposi's Sarcoma and certain cases of HCC.
Area of Science:
- Transplantation Immunology
- Pharmacology
- Nephrology
Background:
- Sirolimus (SRL) is an immunosuppressive drug introduced in 1999 for renal transplant patients.
- SRL functions by inhibiting interleukin-2 (IL-2) signal transduction via FK506-binding proteins (FKBPs).
- Unlike some immunosuppressants, SRL exhibits no significant nephrotoxic, neurotoxic, or diabetogenic effects.
Purpose of the Study:
- To evaluate the efficacy of Sirolimus (SRL) monotherapy in liver transplant recipients.
- To assess SRL's utility in managing specific adverse events associated with other immunosuppressants.
- To explore SRL's role in treating conditions like multifocal HCC and Kaposi's Sarcoma.
Main Methods:
- A cohort of 27 liver transplant patients received Sirolimus (SRL) monotherapy out of 285 total patients.
- SRL monotherapy was initiated for patients experiencing nephrotoxicity, neurotoxicity, or diabetes.
- Indications included multifocal HCC not meeting Milan criteria and Kaposi's Sarcoma.
Main Results:
- Eleven of 14 patients with renal failure showed significant improvement in creatinine levels after SRL monotherapy (mean 1.0 mg/dl).
- Four patients with neurotoxicity experienced complete symptom resolution within days of SRL treatment.
- Two of three patients with Kaposi's Sarcoma achieved remission.
Conclusions:
- Sirolimus (SRL) monotherapy is a viable option for managing calcineurin inhibitor-induced complications.
- SRL monotherapy can be effective in treating Kaposi's Sarcoma post-transplantation.
- SRL monotherapy offers a potential treatment strategy for specific oncological indications in transplant patients.
